-
4 days ago | 
statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year. Before you digest our parting words, a couple of housekeeping notes:
-
5 days ago | 
statnews.com | Matthew Herper
Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of blockbuster drugs Imfinzi and Tecentriq, and VEGF, the target of the blockbuster Avastin.
-
5 days ago | 
statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. We’re going to get to today’s new data in a minute, but first let’s deal with a less serious matter: the marketing of pharmaceutical products via the food attendees need to consume at giant medical meetings. Genentech has been a longtime leader on this front.
-
5 days ago | 
flipboard.com | Adam Feuerstein |Matthew Herper |Angus Chen
In the wake of the recent sweeping federal cuts to the US Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS …
-
5 days ago | 
statnews.com | Matthew Herper
CHICAGO — Each year, 40,000 cancer researchers, doctors, and industry executives gather here for the biggest meeting in oncology. And for seven years, it has been almost assumed that the medicines generating the most buzz will come from AstraZeneca.
-
6 days ago | 
statnews.com | Angus Chen |Matthew Herper
CHICAGO — An exercise program can reduce the risk that colorectal cancer will return after surgery and chemotherapy, according to a new study. The benefit from the study’s exercise program was about as large as what researchers might expect from a new drug, experts said, and came from a randomized controlled trial, the gold standard of medical research. Such studies are common for pharmaceuticals, but are difficult to conduct and unusual for exercise programs.
-
6 days ago | 
statnews.com | Matthew Herper |Adam Feuerstein |Angus Chen
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO is usually sweltering, but it’s surprisingly chilly today. We’re back with a roundup of tragic paradoxes, a race for new breast cancer drugs, and all that jazz. First, though, we want to thank everyone who turned out for our STAT@ASCO event last night.
-
1 week ago | 
statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen
For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. The annual meeting of the American Society of Clinical Oncology is now in session. As always, STAT has your appetite for cancer news covered. Reporters Matt Herper, Adam Feuerstein, and Angus Chen are in Chicago — laptops open, cellphones charged. We’ll be delivering this newsletter, reporting stories, and hosting STAT events over the next four days. Thank you so much for your attention and support.
-
1 week ago | 
statnews.com | Matthew Herper
Robert F. Kennedy Jr.’s unilateral decision that the Centers for Disease Control and Prevention would no longer recommend Covid-19 boosters for healthy people during childhood or pregnancy represents a bulldozing of safeguards intended to keep public health officials honest and their decisions transparent. It also tramples on individuals’ ability to make their own decisions about medical evidence.
-
2 weeks ago | 
statnews.com | Matthew Herper |Casey Ross
The American Society of Clinical Oncology, the largest professional organization in cancer care, announced Wednesday that it had partnered with Google Cloud to develop an AI-based tool to help physicians rapidly question the organization’s guidelines on best practices in diagnosing and treating cancer.
